Laurie B. Keating
2019 - Alnylam Pharmaceuticals
In 2019, Laurie B. Keating earned a total compensation of $2.4M as Executive Vice President, Chief Legal Officer and Secretary at Alnylam Pharmaceuticals, a 50% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $268,750 |
|---|---|
| Option Awards | $1,272,688 |
| Salary | $490,400 |
| Stock Awards | $354,110 |
| Other | $35,732 |
| Total | $2,421,680 |
Keating received $1.3M in option awards, accounting for 53% of the total pay in 2019.
Keating also received $268.8K in non-equity incentive plan, $490.4K in salary, $354.1K in stock awards and $35.7K in other compensation.
Rankings
In 2019, Laurie B. Keating's compensation ranked 4,993rd out of 13,971 executives tracked by ExecPay. In other words, Keating earned more than 64.3% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 4,993 out of 13,971 | 64th |
Division Manufacturing | 1,857 out of 5,701 | 67th |
Major group Chemicals And Allied Products | 654 out of 2,200 | 70th |
Industry group Drugs | 552 out of 1,886 | 71st |
Industry Pharmaceutical Preparations | 412 out of 1,398 | 71st |
Source: SEC filing on April 2, 2021.
Keating's colleagues
We found five more compensation records of executives who worked with Laurie B. Keating at Alnylam Pharmaceuticals in 2019.
2019
John Maraganore
Alnylam Pharmaceuticals
Chief Executive Officer
2019
Jeffrey Poulton
Alnylam Pharmaceuticals
Chief Financial Officer
2019
Yvonne Greenstreet
Alnylam Pharmaceuticals
Chief Operating Officer
2019
Barry Greene
Alnylam Pharmaceuticals
Former President
2019
Akshay Vaishnaw
Alnylam Pharmaceuticals